To evaluate the translational potential of targeting RAD reduction as a treatment for systolic HF we evaluated the impact of RAD knockdown in ex vivo human heart slices from HFrEF patients (Figure 5D). The gene discussed is RRAD; the disease is hydrops fetalis.